Dr Shilpa Gupta speaks to ecancer at the 2020 ASCO GU meeting in San Francisco about the results from the BLASST-1 study.
She describes the methodology of this study, where patients with muscle invasive bladder cancer were treated with a combination of nivolumab, gemcitabine and cisplatin in the neoadjuvant setting before undergoing a radical cystectomy within six to eight weeks.
Dr Gupta outlines the preliminary results from this regimen, which achieved a pathologic response (PaR) of 66 percent. This combination was also found to be safe and effective in these patients.
She believes that immunotherapy will form an important backbone for the neoadjuvant treatment of this disease and states that a phase III study which will investigate this type of regimen more closely is already underway.